|Bid||6.73 x 3200|
|Ask||6.77 x 4000|
|Day's Range||6.57 - 6.95|
|52 Week Range||5.81 - 19.00|
|Beta (5Y Monthly)||0.65|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.33|
Inovio Pharmaceuticals, Inc. ( NASDAQ:INO ) is possibly approaching a major achievement in its business, so we would...
Based on analysts' loftiest price targets, these companies could nearly triple or potentially quintuple investors' money over the next year.
It seems such a long time ago that Inovio Pharmaceuticals (NASDAQ: INO) was considered one of the leaders in the hunt for a COVID-19 vaccine -- but the biotech was left in the dust by peers and many investors have given up on the stock. In the past 12 months, shares of Inovio are down 45% even as the broader market took off. Let's see whether the company is finally ready to turn things around.